| Market Cap | ₹2,845.05 CrGeneral Industrials |
|---|---|
| P/E TTM | 14.25Sector: 50.01 |
| Promoter Holding | 66%Stable ownership |
| Revenue Growth | 185.33%Annual YoY |
| Execution period | Lifetime |
Key highlights
- Licence No. MFG/MD/2026/000784 issued by CDSCO on October 21, 2026, with lifetime validity
- Authorisation covers 8 implant categories including Lattice Acetabular Cups and TLIF/PLIF spinal implants
- Products will be manufactured using Ti6Al4V titanium alloy powder under brand names Neobone and Nubone
- Approval follows the subsidiary obtaining ISO 13485:2016 and ISO 9001:2015 certifications in April 2026
- The licence establishes a regulatory foundation for Jaykay's expansion into the specialized medical devices segment
Strategic Entry Into Specialized Medical Devices
Jaykay Enterprises has achieved a significant regulatory milestone through its wholly-owned subsidiary, JK Digital & Advance Systems. The Central Drugs Standard Control Organisation has granted the firm a lifetime licence to manufacture Class C and Class D medical devices, which represent the highest risk and most technologically advanced categories in the sector. This approval allows the company to produce specialized orthopaedic and spinal implants, establishing a formal presence in the healthcare solutions market.
The development aligns with the company's broader diversification strategy, following its recent ISO 13485:2016 certification for medical device quality management systems awarded earlier this year.
Advanced Titanium Alloy Implant Portfolio
- Lattice Acetabular Cups and Cone Cups for complex hip revision surgeries and bone reconstruction
- Lattice Buttress and Shim Implants designed for structural support and gap-filling in arthroplasty
- Lattice Cage Constructs for reconstructing severe acetabular bone defects in replacement procedures
- TLIF and PLIF Spinal Implants for transforaminal and posterior lumbar interbody fusion procedures
- Lattice Shells and Wedges for the reinforcement of acetabular bone during complex hip surgeries
- All products manufactured using medical-grade titanium alloy powder (Ti6Al4V) under Neobone and Nubone brands
Financial Context and Diversification Momentum
The medical device approval comes as Jaykay Enterprises continues to scale its industrial and aerospace operations. For the quarter ended June 30, 2026, the company reported operating revenue of ₹74.57 crore, a 34.48% increase compared to the same period last year. While the quarterly net profit stood at ₹4.41 crore, the company maintains a robust annual revenue growth rate of 185.33%.
This regulatory clearance for JK Digital complements other group milestones, including a ₹60.01 crore defence order secured by subsidiary Allen Reinforced Plastics in August 2026 and the ongoing ₹154.29 crore rights issue intended to fund expansion across its specialized manufacturing verticals.
| Date | Announcement | Amount |
|---|---|---|
| 18 Sep 2026 | AS9100D and ISO 9001:2015 certifications from MTIC InterCert for aerospace, defence and aviation manufacturingSource: BSE filing | – |
| 18 Aug 2026 | In-principle listing approval from NSE for rights issue of partly paid-up equity sharesSource: jaykayenterprises.com | ₹154.29 Cr |
| 17 Aug 2026 | In-principle listing approval from BSE for rights issue of partly paid-up equity sharesSource: BSE filing | ₹154.29 Cr |
| 11 Aug 2026 | AS9100:D and ISO 9001:2015 aerospace certifications received by subsidiary Allen Reinforced Plastics LimitedSource: BSE filing | – |
| 26 Apr 2026 | ISO 13485:2016 and ISO 9001:2015 medical device certifications awarded to subsidiary JK Digital & Advance Systems by BSCICSource: BSE filing | – |
| 01 Dec 2025 | Listing and trading approval from NSE for direct listing of 13,02,87,066 equity shares on the Main BoardSource: jaykayenterprises.com | – |
What to watch next
- Commercial launch and market distribution of Neobone and Nubone branded implant products
- Announcement of unaudited Q2 FY27 financial results following the trading window closure
- Utilization of ₹154.29 crore rights issue proceeds for medical and aerospace capacity expansion
- Execution progress of the ₹60.01 crore composite parts order from BrahMos Aerospace
| Share price | ₹202.39 |
|---|---|
| Market capitalisation | ₹2,845.05 Cr |
| Revenue (annual) | ₹239.65 Cr |
| Net profit (annual) | ₹232.54 Cr |
| Revenue (latest quarter) | ₹74.57 Cr+21.94% vs previous quarter |
| Net profit (latest quarter) | ₹4.41 Cr-97.55% vs previous quarter |
| P/E (TTM) | 14.25×Sector 50.01× |
| Promoter holding | 66%+0.81% QoQ |
| FII holding | 0.51%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Jaykay Enterprises Ltd regarding the receipt of a manufacturing licence for medical devices by its subsidiary. Market figures from a third-party data provider.
Track Jaykay Enterprises live
Get the next Jaykay Enterprises filing on Telegram seconds after it lands. 15 days free.
